Free Trial
NASDAQ:THTX

Theratechnologies (THTX) Stock Price, News & Analysis

Theratechnologies logo
$1.41 -0.06 (-4.08%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 +0.02 (+1.06%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Theratechnologies Stock (NASDAQ:THTX)

Key Stats

Today's Range
$1.41
$1.50
50-Day Range
$1.40
$1.92
52-Week Range
$1.08
$2.18
Volume
304,607 shs
Average Volume
294,356 shs
Market Capitalization
$64.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Remove Ads
Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

THTX Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Headlines

THTX Stock Analysis - Frequently Asked Questions

Theratechnologies' stock was trading at $1.81 at the start of the year. Since then, THTX stock has decreased by 22.1% and is now trading at $1.41.
View the best growth stocks for 2025 here
.

Theratechnologies Inc. (NASDAQ:THTX) issued its quarterly earnings data on Thursday, October, 10th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $22.60 million for the quarter.

Theratechnologies's stock reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

The following companies are subsidiaries of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theratechnologies investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), CymaBay Therapeutics (CBAY), Novo Nordisk A/S (NVO), Adobe (ADBE) and Celestica (CLS).

Company Calendar

Last Earnings
10/10/2024
Today
4/03/2025
Next Earnings (Estimated)
4/09/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:THTX
Employees
140
Year Founded
1993

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
141.00
P/E Growth
N/A
Net Income
$-23,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$85.87 million
Price / Cash Flow
N/A
Book Value
($0.45) per share
Price / Book
-3.13

Miscellaneous

Free Float
N/A
Market Cap
$64.83 million
Optionable
Optionable
Beta
1.11

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:THTX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners